Boston Scientific has acquired Nalu Medical for around $533m, broadening the therapeutic scope of the medtech giant’s neuromodulation portfolio.
California-based Nalu’s Neurostimulation System is designed to address chronic pain in regions such as the shoulder, lower back and knee via peripheral nerve stimulation (PNS).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Driven by an implantable pulse generator powered by a small wearable disc that can be controlled via a smartphone app, the system delivers mild electrical pulses to interrupt pain signals before they reach the brain.
“Peripheral nerve stimulation is an exciting field with a significant unmet patient need,” said Jim Cassidy, president of neuromodulation at Boston Scientific.
“Adding the highly differentiated Nalu Medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations,” Cassidy added.
Nalu’s system gained clearance from the US Food and Drug Administration (FDA) in 2019 and was supported by the COMFORT (NCT04564534) and COMFORT 2 (NCT05204191) randomised controlled trials that evaluated the system’s safety and efficacy. In COMFORT, 87% of participants reported more than a 50% reduction in pain at 12 months, while in COMFORT 2, 79% of patients reached an average pain relief of 64% at six months.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPending customary closing conditions, Boston Scientific expects to complete the transaction by the first half of 2026, with Nalu expected to generate sales over $60m in 2025 and deliver year-over-year growth in excess of 25% in 2026.
Nalu’s offering joins other devices in Boston’s chronic pain management portfolio, including its WaveWriter Alpha Spinal Cord Stimulator (SCS) system for chronic spinal pain caused by conditions such as failed back surgery syndrome (FBSS) and peripheral neuropathy. Falling under the Neuromodulation segment of Boston’s Medsurg business, the Massachusetts-based company’s Q2 2025 financials revealed growth of 7.2% to $303m in the segment versus $282m in the same period of 2024.
According to GlobalData analysis, the neuromodulation market is expected to grow at a compound annual growth rate (CAGR) of 6.8% to a valuation of $12.3bn by 2034, up from $6.3bn in 2024.
